Pliant Therapeutics Inc. (PLRX)
NASDAQ: PLRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PLRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $36.89M
- EPS (TTM)
- -$1.46
- Dividend yield
- None
- 52-week range
- 0.5719 – 1.67
- Day range
- 0.5719 – 0.6139
- Volume / Avg
- 933.40K / 408.93K
- Beta
- —
- Shares outstanding
- 61.99M
52-week range
PLRX stock today
On Nov 20, PLRX ended the session at $0.5951, shedding $0.0249 (4.02%), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 933.40K shares, a sign of unusually heavy trading. At this level, PLRX sits near the bottom of its 52-week range of $0.5719 to $1.67: 64.4% below the high, set on Dec 4, 2025 and 4.1% above the low.
PLRX is down 51.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 61.6%. Pliant Therapeutics has posted a net loss over the last twelve months (EPS of -$1.46), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pliant Therapeutics
Company profilePliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 49
- IPO year
- 2020
- Website
- pliantrx.com
Financial highlights
Full financialsIn fiscal 2025, Pliant Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Pliant Therapeutics reported a net loss of $149.3 million, compared with a loss of $210.3 million a year earlier. Diluted earnings per share came in at -$2.43.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.58M | $9.69M | $7.57M |
| Growth | — | -100.00% | -83.69% | +27.91% | -81.89% |
| Net income | $-149.34M | $-210.30M | $-161.34M | $-123.32M | $-97.26M |
| EPS (diluted) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$2.00+236.08%
- Strong buy 0
- Buy 0
- Hold 3
- Sell 0
- Strong sell 1
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.43 vs $-0.37
- Surprise
- -16.22%
PLRX news
All PLRX news- Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswire
- Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswire
- Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)GlobeNewswire
- Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026GlobeNewswire
- Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 DevelopmentNasdaqAMGN, BCAX, PLRX
Pliant Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SDEVStablecoin Development Corporation | 0.50 | -10.30% | $36.90M | vs PLRX |
| GRCEGrace Therapeutics Inc. | 1.71 | -0.58% | $35.97M | vs PLRX |
| CNTBConnect Biopharma Holdings Limited | 0.59 | -6.08% | $38.05M | vs PLRX |
| CUECue Biopharma Inc. | 4.15 | -7.78% | $34.69M | vs PLRX |
| DWTXDogwood Therapeutics Inc. | 1.04 | -2.36% | $39.57M | vs PLRX |
| VERUVeru Inc. | 1.94 | -8.06% | $33.08M | vs PLRX |
| ATNMActinium Pharmaceuticals Inc. (Delaware) | 1.05 | -1.87% | $33.01M | vs PLRX |
| TLPHTalphera Inc. | 0.7852 | +6.25% | $40.80M | vs PLRX |
Indexes, lists and sector
Pliant Therapeutics stock FAQ
What is Pliant Therapeutics's stock price today?
PLRX last traded at $0.5951 as of Nov 20, 4:00 PM EST, down 4.02% on the day. Prices are delayed at least 15 minutes.
Who is Pliant Therapeutics's CEO?
Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D. is the chief executive officer of Pliant Therapeutics Inc., which has about 49 employees.
What is the PLRX 52-week high?
The 52-week high for PLRX is $1.67 and the 52-week low is $0.5719. The stock is currently 64.4% below its high.